Wide Ranks

GILD

Gilead Sciences, Inc.

92.41

Top Statistics
Market Cap 115 B Forward PE 12.33 Revenue Growth 7.00 %
Current Ratio 1.26 Trailing PE 1026.78 Earnings Growth -42.20 %
Profit Margins 0.45 % Peg Ratio Dividend Yield 3.33 %
Enterprice / EBITA 9.44 Enterprise / Revenue 4.65 Price To Sales Trailing12 Months 4.07
Profitability
Profit Margins 0.45 % Operating Margins 41.96 %
Balance Sheet
Total Cash 6 B Total Cash Per Share 5.37 Total Debt 23 B
Total Debt To Equity 126.42 Current Ratio 1.26 Book Value Per Share 14.83
All Measures
Short Ratio 265.00 % Message Board Id finmb_29002 Fax 650 578 9264
Shares Short Prior Month 16 M Return On Equity 0.0056 City Foster City
Uuid 8659e669-8ec5-3b0f-9929-db5db506231f Previous Close 91.35 First Trade Date Epoch Utc 696 M
Book Value 14.83 Beta 0.1920 Total Debt 23 B
Volume 5 M Price To Book 6.23 Last Split Date 1 B
Fifty Two Week Low 62.07 Total Cash Per Share 5.37 Total Revenue 28 B
Shares Short Previous Month Date 1 B Target Median Price 97.00 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Operating Margins 41.96 %
Last Dividend Value 0.7700 Target Mean Price 97.20 Net Income To Common 126 M
Short Percent Of Float 0.0145 Implied Shares Outstanding 1 B Trailing Peg Ratio 53.26 %
Last Fiscal Year End 1 B Average Daily Volume10 Day 7 M Average Volume10days 7 M
Total Cash 6 B Next Fiscal Year End 1 B Revenue Per Share 22.70
Held Percent Insiders 0.0012 Ebitda Margins 49.29 % Dividend Rate 3.08
Trailing PE 1026.78 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 91.35 Target Low Price 69.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 87.91 Open 91.44 Dividend Yield 3.33 %
State CA Free Cashflow 9 B Return On Assets 0.1196
Time Zone Short Name EST Trailing Eps 0.0900 Day Low 91.44
Address1 333 Lakeside Drive Trailing Annual Dividend Rate 3.06 Price Hint 2
Shares Outstanding 1 B Target High Price 125.00 Website https://www.gilead.com
52 Week Change 0.2064 Average Volume 6 M Earnings Quarterly Growth -42.50 %
Forward Eps 7.43 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 96.20 % Last Split Factor 2:1 Regular Market Day High 92.89
Is_sp_500 True Profit Margins 0.45 % Debt To Equity 126.42
Fifty Two Week High 98.90 Day High 92.89 Shares Short 18 M
Regular Market Open 91.44 Industry Key drug-manufacturers-general Earnings Growth -42.20 %
Enterprise To Revenue 4.65 Revenue Growth 7.00 % Shares Percent Shares Out 0.0145
Operating Cashflow 10 B Five Year Avg Dividend Yield 402.00 % Currency USD
Market Cap 115 B Time Zone Full Name America/New_York Is_nasdaq_100 True
Zip 94404 Payout Ratio 3400.00 % Quote Type EQUITY
Industry Drug Manufacturers - General Ex Dividend Date 1 B Regular Market Day Low 91.44
Held Percent Institutions 0.8840 Long Name Gilead Sciences, Inc. Current Price 92.41
Enterprise To Ebitda 9.44 Financial Currency USD Trailing Annual Dividend Yield 3.35 %
Current Ratio 1.26 Gross Margins 77.81 % Industry Disp Drug Manufacturers - General
Number Of Analyst Opinions 29 Country United States Float Shares 1 B
Two Hundred Day Average 75.43 Ir Website http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome Enterprise Value 131 B
Price To Sales Trailing12 Months 4.07 Forward PE 12.33 Regular Market Volume 5 M
Last Dividend Date 1 B Ebitda 13 B Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.

The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.

; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.

V.

for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.

The company was incorporated in 1987 and is headquartered in Foster City, California.